Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDE | P14735 | 1/20 | 0.49 |
| ▸ | UBE2N | P61088 | 1/20 | 0.49 |
| ▸ | TACR1 | P25103 | 16/20 | 0.45 |
| ▸ | MITF | O75030 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA4 | P22748 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | TACR2 | P21452 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8478086 | 1.00 | IDE (0.49) | IDEUBE2NTACR1MITFCA1 | |
| SCHEMBL7825901 | 0.85 | TACR1 (0.51) | TACR1CA1CA2CA4CA9 | |
| SCHEMBL8480574 | 0.85 | TACR1 (0.51) | TACR1CA1CA2CA4CA9 | |
| Hydrochloric Acid SCHEMBL8478985 | 0.84 | TACR1 (0.50) | TACR1CA1CA2CA4CA9 | |
| Hydrochloric Acid SCHEMBL7815938 | 0.84 | TACR1 (0.50) | TACR1CA1CA2CA4CA9 | |
| SCHEMBL7466926 | 0.84 | IDE (0.66) | IDEUBE2NTACR1MITFCA1 | |
| SCHEMBL7829861 | 0.83 | TACR1 (0.49) | TACR1CA1CA2CA4CA9 | |
| SCHEMBL1256779 | 0.81 | TACR1 (0.62) | TACR1 | |
| SCHEMBL7829090 | 0.81 | TACR1 (0.62) | TACR1 | |
| SCHEMBL1512947 | 0.81 | TACR1 (0.62) | TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1176144-B1 | N-triazolylmethyl-piperazine derivatives as neurokinine receptor-antagonists | SOLVAY PHARM GMBH (DE) | 2003-07-09 | — | — | EP | disclosed |
| US-6407106-B1 | FOR THERAPY OF INFLAMMATORY DISTURBANCES OF THE GASTROINTESTINAL TRACT | SOLVAY PHARMACEUTICALS GMBH (DE) | 2002-06-18 | — | — | US | disclosed |
| US-20020065276-A1 | N-triazolymethyl-piperazine compounds with neurokinin-receptor antagonist activity | SOLVAY PHARMACEUTICALS GMBH (DE) | 2002-05-30 | — | — | US | disclosed |
| EP-1176144-A1 | N-triazolylmethyl-piperazine derivatives as neurokinine receptor-antagonists | Solvay Pharmaceuticals GmbH (DE) | 2002-01-30 | — | — | EP | disclosed |
| EP-0655442-B1 | Piperazine derivatives as Tachykinin antagonists | FUJISAWA PHARMACEUTICAL CO (JP) | 2001-05-23 | — | — | EP | disclosed |
| EP-0655442-A1 | Piperazine derivatives as Tachykinin antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065276-A1 | N-triazolymethyl-piperazine compounds with neurokinin-receptor antagonist activity | NPSR1, NTSR2, NTSR1 | IDE 3344/4885UBE2N 2995/4885TACR1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.